FNA Tumor Sampling for CD137 Modulation: A Pilot Study

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by Stanford University
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
First received: April 23, 2010
Last updated: February 11, 2015
Last verified: February 2015

This research involves the study of cancer cells in order to better understand how the body's immune system responds to therapy with monoclonal antibodies. This study may lead to the development of special materials that could be used, in the future, to treat head and neck cancer or to follow the response to treatment.

Condition Intervention
Head and Neck Cancer
Breast Cancer
Head and Neck Cancers
Procedure: FNA Biopsy

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: FNA Tumor Sampling for CD137 Modulation: A Pilot Study

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • evaluation of change in CD137 positive NK cells in blood & tumors in response to therapeutic moAbs [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluation of activation status of CD137 positive NK cells [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 24
Study Start Date: March 2010
Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Fine needle aspiration (FNA) biopsies
Fine needle aspiration biopsies (FNA) will be performed prior to and 0 to 336 hours after the therapeutic monoclonal antibody infusion.
Procedure: FNA Biopsy


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

ALL Patients:

  1. Patient must have histologically confirmed CD20+ tumor (non-Hodgkin lymphoma), squamous cell carcinoma of the head and neck, HER2+ breast adenocarcinoma, or colorectal adenocarcinoma.
  2. Patients must not have received any immunosuppressive or anti cancer agent within 2 weeks prior to the first planned FNA biopsy.
  3. The patient?s therapeutic plan must include either rituximab, cetuximab/panitumumab or trastuzumab to be administered on a schedule such that a FNA biopsy can be done within one week prior, and/or peripheral blood drawn immediately prior to the first dose of the therapeutic mAb and 24-72 hours post dose. Patients not receiving any other anti-cancer or immunosuppressive (steroids) modality within that time frame are preferred, though use of such agents does not exclude them from the study.
  4. Patients not receiving any immunosuppressive or anti-cancer agent within 2 weeks prior to the first planned FNA biopsy are preferred.
  5. Informed consent must occur and be documented per institutional rules prior to the first planned FNA biopsy and blood draw.

Patients Providing an FNA in addition to Blood Samples: Criteria applicable to FNA, and not required for patients providing PBMCs without FNA. Patients without tumors amenable to FNA will be candidates for blood sampling only.

If patients do not meet inclusion criteria, then they will be excluded from participating in this study.

  1. Patients must have a normal WBC and platelet count, must have no evidence of coagulopathy and must not have received irreversible platelet inhibitors (aspirin) for 2 weeks and reversible platelet inhibitors (other NSAIDS) for one week prior to the initial FNA biopsy.
  2. Patients may not be taking therapeutic anticoagulation (target INR of >=2) (warfarin or heparin).
  3. Patients must have tumor masses amenable to minimally invasive fine needle aspiration by direct visualization and/ or palpation of the tumor. Generally this will be a biopsy of the primary tumor site or superficial regional lymph nodes.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01114256

United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Risa Jiron    650-736-1598    rjiron@stanford.edu   
Contact: Cancer Clinical Trials Office    (650) 498-7061      
Principal Investigator: Dimitrios Colevas         
Sub-Investigator: Holbrook Kohrt         
Sub-Investigator: Ron Levy         
Sub-Investigator: Christina Kong         
Sponsors and Collaborators
Stanford University
Principal Investigator: Dr. A. Dimitrios Colevas Stanford University
  More Information

No publications provided

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01114256     History of Changes
Other Study ID Numbers: VAR0053, SU-04072010-5602
Study First Received: April 23, 2010
Last Updated: February 11, 2015
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on May 21, 2015